Aug-13-19 Antibe Announces Closing of Public Offering
Aug-07-19 Antibe Therapeutics Announces Filing of Final Short Form Prospectus
Jul-25-19 Antibe Therapeutics Announces Size of Offering
Jul-23-19 Antibe Therapeutics Announces Offering of Units
Jul-16-19 Antibe Therapeutics Reports 2019 Year-End Financial and Operating Results
Jul-02-19 Antibe Therapeutics Announces Results of Annual General and Special Meeting
Jun-25-19 Antibe Therapeutics Announces CEO Letter to Shareholders
Jun-03-19 Antibe Therapeutics Unveils Lead Indication for ATB-352, a Potent, Non-Addictive Analgesic for Severe Pain
May-30-19 Antibe Therapeutics Announces Upcoming Conference Schedule
Apr-26-19 Antibe Therapeutics to Present at 2019 Bloom Burton & Co. Healthcare Investor Conference
Apr-16-19 Phase 2B GI Safety Results for ATB-346 Published in British Journal of Pharmacology
Mar-29-19 Antibe Therapeutics Announces Commencement of Phase 2B Dose-Ranging, Efficacy Study for Lead Drug, ATB-346
Feb-27-19 Antibe Therapeutics Announces Closing of $5.75 Million Bought Deal Offering
Feb-22-19 Antibe Therapeutics Recognized as a 2019 TSX Venture 50 Company
Feb-15-19 Antibe Therapeutics Reports Q3 2019 Interim Financial and Operating Results
Feb-04-19 Antibe Therapeutics Announces $5 Million Bought Deal Offering
Jan-21-19 Antibe Therapeutics Receives Approval to Initiate Part Two of Phase 2B Dose-Ranging, Efficacy Study for ATB-346
Dec-19-18 Antibe Therapeutics Raises $1.6 Million Through Warrant Exercises
Nov-30-18 Antibe Therapeutics to Present at the 11th Annual LD Micro Main Event on December 4, 2018
Nov-27-18 Antibe Therapeutics Announces Successful Completion of Part One of Phase 2B Dose-Ranging, Efficacy Study for ATB-346